{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["38(4)"],"submitter":["Kiepura A"],"pubmed_abstract":["<h4>Background</h4>Nonalcoholic fatty liver disease (NAFLD) constitutes an independent risk factor for the development of coronary heart disease. Low-grade inflammation has been shown to play an important role in the development of atherosclerosis and NAFLD. Free fatty acid receptor 4 (FFAR4/GPR120), which is involved in damping inflammatory reactions, may represent a promising target for the treatment of inflammatory diseases. Our objective was to evaluate the effect of TUG-891, the synthetic agonist of FFAR4/GPR120, on fatty liver in vivo.<h4>Methods</h4>The effect of TUG-891 on fatty liver was investigated in apoE<sup>-/-</sup> mice fed a high-fat diet (HFD), using microscopic, biochemical, molecular, and proteomic methods.<h4>Results</h4>Treatment with TUG-891 inhibited the progression"],"journal":["Cardiovascular drugs and therapy"],"pagination":["667-678"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11266261"],"repository":["biostudies-literature"],"pubmed_title":["The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice."],"pmcid":["PMC11266261"],"pubmed_authors":["Kus K","Wisniewska A","Ulatowska-Bialas M","Olszanecki R","Czepiel K","Stachyra K","Kiepura A","Suski M"],"additional_accession":[]},"is_claimable":false,"name":"The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice.","description":"<h4>Background</h4>Nonalcoholic fatty liver disease (NAFLD) constitutes an independent risk factor for the development of coronary heart disease. Low-grade inflammation has been shown to play an important role in the development of atherosclerosis and NAFLD. Free fatty acid receptor 4 (FFAR4/GPR120), which is involved in damping inflammatory reactions, may represent a promising target for the treatment of inflammatory diseases. Our objective was to evaluate the effect of TUG-891, the synthetic agonist of FFAR4/GPR120, on fatty liver in vivo.<h4>Methods</h4>The effect of TUG-891 on fatty liver was investigated in apoE<sup>-/-</sup> mice fed a high-fat diet (HFD), using microscopic, biochemical, molecular, and proteomic methods.<h4>Results</h4>Treatment with TUG-891 inhibited the progression","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-05-27T12:12:29.638Z","creation":"2026-05-27T03:07:28.636Z"},"accession":"S-EPMC11266261","cross_references":{"pubmed":["36705799"],"doi":["10.1007/s10557-023-07430-7"]}}